New (alternative) temozolomide regimens for the treatment of glioma

Neuro-Oncology

Volumn 11, Issue 1, 2009, Pages 69-79

  Wick, Wolfgang ^a,b   Platten, Michael ^a   Weller, Michael ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Brain tumor; Glioma; MGMT; O6 methyl guanine DNA methyltransferase; Temozolomide

Indexed keywords

ALPHA INTERFERON; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DNA ALKYLATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEVER; GLIOBLASTOMA; GLIOMA; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMOCYSTIS PNEUMONIA; RADIATION DOSE; RECURRENT CANCER; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; GLIOMA; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 61449171080     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-078     Document Type: Review

References (66)

1. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
2. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
4. Stevens MFG, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47:5846-5852.
5. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-291.
6. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23: 35-61.
7. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367.
8. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmaco-logic disruption of base excision repair sensitizes mismatch repair- deficient and-proficient colon cancer cells to methylating agents. Clin Cancer Res. 1999;5:2908-2917.
9. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005;65:6394-6400.
10. Tentori L, Graziani G. Pharmacological strategies to increase the anti- tumor activity of methylating agents. Curr Med Chem. 2002;9:1285-1301.
11. Bignami M, O'Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res. 2000;462:71-82.
12. 6- methylguanine. Oncogene. 2007;26:186-197.
13. Stupp R, Dietrich P-Y, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-1382.
14. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
15. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
16. 6- methylguanine- deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3- (2-chloroethyl)-3-nitrosourea- based chemotherapy. Neurosurgery. 2004;54:349-357.
17. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995;51:167-223.
18. Tano K, Shiota S, Collier J, Foote RS, Mitra S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Natl Acad Sci USA. 1990;87:686-690.
19. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-4199.
20. 6-methylguanine-DNA methyltrans-ferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797.
21. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochro- matinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997;17:5612-5619.
22. Blanc JL, Wager M, Guilhot J, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol. 2004;68:275-283.
23. Gonzalez-Gomez P, Bello MJ, Arjona D, et al. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol. 2003;22:601-608.
24. Hotta T, Saito Y, Fujita H, et al. O6-alkylguanine-DNA alkyltrans- ferase activity of human malignant glioma and its clinical implications. J Neurooncol. 1994;21:135-140.
25. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigmsan update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-180.
26. 6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res. 1999;59:2402-2410.
27. 6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 2001;7:2309-2317.
28. Lee SM, Thatcher N, Crowther D, Margison GP. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer. 1994;69:452-456.
29. 6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro-Oncology. 2004;6:28-32.
30. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357-3361.
31. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer. 2000;88:469-473.
32. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22:610-616.
33. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.
34. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372-2377.
35. Buttolo L, Giunta F, Ferrari VD, Grisanti S, Marini G, Mortini P. Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: a 6-year experience [abstract 1511]. J Clin Oncol. 2006;24(suppl):60s.
36. Caroli M, Locatelli M, Campanella R, et al. Temozolomide in glioblas- toma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J Neurooncol. 2007;84:71-77.
37. Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-meth- ylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolo- mide. J Clin Oncol. 2007;25:1470-1475.
38. Combs SE, Gutwein S, Schulz-Ertner D, et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol. 2005;181:372-377.
39. Combs SE, Schulz-Ertner D, Welzel T, Bischof M, Debus J. Re-irradiation using high precision radiotherapy and concomitant temozolomide in patients with recurrent glioma: re-challenge with radio-chemotherapy [abstract 12517]. J Clin Oncol. 2007;25(suppl):606s.
40. D'Agostino G, Balducci M, Anile C, et al. An analysis of two different schedules of radiochemotherapy with concomitant temozolomide in high grade gliomas [abstract 2035]. J Clin Oncol. 2007;25(suppl):83s.
41. Montemaggi P, Guerrieri P, Mortellaro G, Piazza D, Rizzo S. Temo- zolomide (TMZ) in radio-chemotherapy combined schedule for treatment of newly-diagnosed high-grade gliomas(HGG) [abstract 1578]. J Clin Oncol. 2005;23(suppl):133s.
42. Neurooncological Working Group of the German Cancer Society. NOA-08: temozolomide (one week on/one week off) versus radiotherapy for first-line therapy of anaplastic astrocytoma and glioblastoma in the elderly: a randomized phase III study (methvsalem). Available at: www.neuroonkologie.de. Accessed February 5, 2008.
43. Sul J, Panageas KS, Lassman AB, et al. A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cisretinoic acid for patients with newly diagnosed glioblastoma multi-forme (GBM) [abstract 2031]. J Clin Oncol. 2007;25(suppl):82s.
44. Zorlu F, Sari S, Ozyigit G, et al. Therapeutic results in patients with an aplastic astrocytoma (AA) or glioblastoma multiforme (GBM) receiving postoperative radiotherapy and concomitant temozolomide [poster]. Presented at: ECCO 13-the European Cancer Conference; October 30-November 3, 2005; Paris, France.
45. Chinot O, Barrie M, Cournede A, et al. Phase II study of temozolomide (TMZ) administered on a 7 days on-7days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM) [abstract 1523]. J Clin Oncol. 2005; 23(suppl):119s.
46. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710.
47. Brada M, Ashley S, Dowe A, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolo- mide. Ann Oncol. 2005;16:942-949.
48. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857.
49. Gilbert MR, Friedman HS, Kuttesch JF, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-Oncology. 2002;4:261-267.
50. Clarke J, Sul J, DeAngelis L, et al. A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis- retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM) [Abstract MA-557]. Neuro-Oncology. 2007:530.
51. 51.European Organisation for Research and Treatment of Cancer. Brain Tumour Group: Ongoing Trials. Available at http://groups.eortc.be/ brain/html/trials.html. Accessed February 5, 2008.
52. National Cancer Institute. Radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma or gliosar- coma. Available at http://www.clinicaltrials.gov/ct/gui/show/NCT00304031?order=1. Accessed February 5, 2008.
53. Balmaceda C, Peereboom D, Pannullo S, et al. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008;112:1139-1146.
54. Berrocal A, Perez-Segura P, Gil M, et al. Phase II study of extended schedule temozolomide in refractory gliomas [abstract 1516]. J Clin Oncol. 2006;24(suppl):62s.
55. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer. 2006;95:1155-1160.
56. 2 a day for 21 days every 28: a GICNO (Italian Neuro-Oncology Group) study [abstract 1541]. J Clin Oncol. 2005;23(suppl) 124s.
57. D'Amico A, Gabbani M, Dall'oglio S, et al. Protracted administration of low doses of temozolomide (TMZ) in the treatment of relapse glioblastoma (GBM) enhances the antitumor activity of this agent [abstract 1572]. J Clin Oncol. 2006;23(suppl):75s.
58. Donfrancesco A, Milano GM, Jenkner A, et al. Temozolomide in resistant or relapsed neuroblastoma [abstract 8522]. J Clin Oncol. 2005;23(suppl):805s.
59. Jauch T, Hau P, Bogdahn U. Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas (HGG) [abstract 2034]. J Clin Oncol. 2007;25(suppl):83s.
60. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology. 2002;4:39-43.
61. Neyns B, Chaskis C, Joosens E, et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest. 2008;26:269-277.
62. Strik HM, Buhk JH, Bock HC, Nitsche M, Giese A, Baehr M. Rechallenge of malignant gliomas with temozolomide-can it be effective? [abstract 2072]. J Clin Oncol. 2007;25(suppl): 93s.
63. Wen PY, Schiff D, Doherty L, et al. A phase II study of prolonged daily temozolomide for low-grade glioma [abstract 1522]. J Clin Oncol. 2005;23(suppl):119s.
64. Perry JR, Mason WP, Belanger K, et al. The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intensive temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma [abstr. 2010]. J. Clin Oncol. 2008;26(suppl):15s.
65. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004;62:2113-2115.
66. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol. 2005;23:4235-4236.